9,414 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by J. Goldman & Co LP

J. Goldman & Co LP bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,414 shares of the company’s stock, valued at approximately $1,154,000.

A number of other hedge funds have also bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Protagonist Therapeutics during the second quarter worth $1,263,535,000. Johnson & Johnson purchased a new stake in shares of Protagonist Therapeutics during the second quarter valued at $300,220,852,000. Janus Henderson Group PLC increased its position in shares of Protagonist Therapeutics by 140.7% in the 4th quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock valued at $231,355,000 after acquiring an additional 1,549,160 shares during the period. Wellington Management Group LLP raised its stake in Protagonist Therapeutics by 66.2% in the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after acquiring an additional 1,262,977 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after acquiring an additional 1,156,461 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Up 0.6%

Shares of PTGX opened at $151.50 on Thursday. The company has a market capitalization of $9.80 billion, a price-to-earnings ratio of 147.09 and a beta of 1.78. Protagonist Therapeutics, Inc. has a 52 week low of $54.50 and a 52 week high of $160.81. The stock’s 50-day moving average price is $137.15 and its 200-day moving average price is $111.81.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The company had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. The firm’s quarterly revenue was up 3746.8% on a year-over-year basis. As a group, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 4.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the transaction, the director directly owned 7,825 shares in the company, valued at $922,880.50. The trade was a 53.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 34,239 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $148.52, for a total transaction of $5,085,176.28. Following the sale, the chief executive officer directly owned 523,478 shares in the company, valued at $77,746,952.56. This trade represents a 6.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 127,000 shares of company stock worth $17,818,139 in the last ninety days. Corporate insiders own 5.19% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on PTGX. TD Cowen reiterated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Wolfe Research assumed coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective for the company. Citizens Jmp lifted their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Weiss Ratings upgraded Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, BMO Capital Markets increased their price target on shares of Protagonist Therapeutics from $112.00 to $178.00 and gave the stock an “outperform” rating in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $140.53.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.